P PRIMESTOCKFINDER.COM

AR9 Shares archTIS Limited

BUY ASX · ASX
$0.07 -2.86% Prices as of close 2026-10-26

Information-rights management software benefits from data-governance and secure collaboration requirements.

  • ▸Strong historical momentum and data-security demand
  • ▸Above 50-day MA (+10.46%)

Trend: AR9 is trading above the 50-day average (+16.67%), RSI 36 — neutral momentum, with a 3-month return of +27.27%.

Valuation & quality: archTIS Limited trades on forward P/E -8.8, price-to-book 2.12; fundamentals show net margin -119.8%, return on equity -150.3%, revenue growth 120.0% year on year.

Our screen: BUY (score 2) — Information-rights management software benefits from data-governance and secure collaboration requirements.

Computed from end-of-day data; not personal advice.

0.09 0.04 FebMarAprMayJunJulAugSepOct
Daily close, 2026-02-08 → 2026-10-25 (AUD). Range 0.04 – 0.09.
Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
-22.20%-14.30%+16.70%+0.00%-28.60%-20.00%+100.00%-12.50%
Market cap
$34.5M
P/E (ttm)
-8.5
Forward P/E
-8.8
EPS (ttm)
$-0.04
Price / book
2.12
Beta
0.87
Net margin
-119.8%
ROE
-150.3%
Revenue growth
120.0%
Revenue (ttm)
$13.4M
Free cash flow
$-5,913,765
Debt / equity
54%
52-wk range
$0.04 – $0.15
Volume
235,898
Avg volume (3m)
1,012,685
RSI (14)
35.7
vs 50-day MA
+16.67%
1-mo return
-11.39%
3-mo return
+27.27%
Volume z-score
-1.11

archTIS Limited engages in the design and development of products, solutions, and services for secure information sharing and collaboration in Australia and internationally.

Sector: Technology · Industry: Software - Infrastructure · Australia · Website

Browse: all ASX stocks · Cybersecurity picks · today's movers

General information only (Australia). This is general information, not financial product advice. It doesn't consider your objectives, financial situation or needs — consider its appropriateness and seek licensed advice before acting. Not a recommendation to buy or sell any financial product.

Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.